Processa Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

Stock-based Compensation (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2019

Dec. 31, 2018

The fair value of our option awards granted during the year ended December 31, 2018 was estimated using the following assumptions:


Risk-free rate of interest	3.09	%
Expected term (years)	5.0 to 6.25
Expected stock price volatility	85.31	%
Dividend yield	0	%

The following table summarizes our stock option activity for the year ended December 31, 2018:

	Total options Outstanding		Weighted average exercise price		Weighted average remaining contractual life (in years)
Outstanding as of January 1, 2018		-	$	-		-
Options granted		384,400		2.92		9.9
Exercised		-		-		-
Forfeited		-		-		-
Outstanding as of December 31, 2018		384,400	$	2.92		9.9

The allocation of stock-based compensation expense between research and development and general and administrative expense was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and Development	$	88,707	$	-	$	92,111	$	-
General and Administrative		180,422		50,528		302,053		50,528
	$	269,129	$	50,528	$	394,164	$	50,528